These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 739345)

  • 21. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.
    Galanello R; Kattamis A; Piga A; Fischer R; Leoni G; Ladis V; Voi V; Lund U; Tricta F
    Haematologica; 2006 Sep; 91(9):1241-3. PubMed ID: 16956824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Desferrioxamine in thalassaemia.
    Diwany M; Gabr M; el Hefni A; Mokhtar N
    Arch Dis Child; 1968 Jun; 43(229):340-3. PubMed ID: 5652711
    [No Abstract]   [Full Text] [Related]  

  • 23. [Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
    Esposito L; Ferrara M; Galdo Capotorti M
    Pediatria (Napoli); 1978 Mar; 86(1):69-76. PubMed ID: 683795
    [No Abstract]   [Full Text] [Related]  

  • 24. Glucose tolerance and chelation therapy in patients with thalassaemia major.
    Capra L; Atti G; De Sanctis V; Candini G
    Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709
    [No Abstract]   [Full Text] [Related]  

  • 25. Long-term desferrioxamine therapy in thalassemia.
    Modell CB; Beck J
    Ann N Y Acad Sci; 1974; 232(0):201-10. PubMed ID: 4528634
    [No Abstract]   [Full Text] [Related]  

  • 26. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hearing impairment during deferoxamine therapy for thalassemia major.
    Argiolu F; Diana G; Avignone A; Cao A; Di Ninni S
    J Pediatr; 1991 May; 118(5):826-7. PubMed ID: 2019945
    [No Abstract]   [Full Text] [Related]  

  • 28. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
    Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple transfused thalassemia major: ocular manifestations in a hospital-based population.
    Taneja R; Malik P; Sharma M; Agarwal MC
    Indian J Ophthalmol; 2010; 58(2):125-30. PubMed ID: 20195035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine.
    Marsh MN; Holbrook IB; Clark C; Shaffer JL
    Postgrad Med J; 1981 Sep; 57(671):582-4. PubMed ID: 7329898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results of long term iron chelation treatment with deferoxamine.
    Davis BA; Porter JB
    Adv Exp Med Biol; 2002; 509():91-125. PubMed ID: 12572991
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of iron overload in Cooley's anemia.
    Cohen A; Mizanin J; Schwartz E
    Ann N Y Acad Sci; 1985; 445():274-81. PubMed ID: 3860130
    [No Abstract]   [Full Text] [Related]  

  • 34. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early iron overload in beta-thalassaemia major: when to start chelation therapy?
    Fargion S; Taddei MT; Gabutti V; Piga A; Di Palma A; Capra L; Fontanelli G; Avanzini A
    Arch Dis Child; 1982 Dec; 57(12):929-33. PubMed ID: 7181522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose desferrioxamine as a cause of growth failure in thalassemic patients.
    Piga A; Luzzatto L; Capalbo P; Gambotto S; Tricta F; Gabutti V
    Eur J Haematol; 1988 Apr; 40(4):380-1. PubMed ID: 3366230
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 39. Bull's eye maculopathy with deferoxamine.
    Bansal V; Elgarbly I; Ghanchi FD; Atkinson PL
    Eur J Haematol; 2003 Jun; 70(6):420-1. PubMed ID: 12756028
    [No Abstract]   [Full Text] [Related]  

  • 40. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
    Giardina PJ; Ehlers KH; Engle MA; Grady RW; Hilgartner MW
    Ann N Y Acad Sci; 1985; 445():282-92. PubMed ID: 3860132
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.